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Abstract - The fungal polypeptides zervamicins, antiamoebins and efra- 
peptins have been fractionated into several polypeptide components by 
HPLC. A zervamicin fraction lacking tryptophan has been characterized 
and shown to possess an N-terminal leucine residue. The conformations 
of zervamicin IIA and a synthetic analog in solution are compared with 
those determined for the related peptide, antiamoebin. The results are 
consistent with a completely helical structure for the apolar analog of 
zervamicin in chloroform, with partial unfolding in dimethylsulfoxide. 
A similar conformation has been determined for natural zervamicin IIB. 
A synthetic analog of efrapeptin forms a continuous helix in apolar 
solvents while, partial unfolding is seen in polar solvents. Natural 
zervamicin is an effective uncoupler of mitochondrial oxidative phos- 
phorylation. Significant differences in membrane modifying activity 
are noted for the natural peptide and the synthetic apolar analog of 
zervamicin. 
Peptides of fungal origin containing a high proportion of d-aminoisobutyric acid (Aib) 
have been the focus of intensive investigations (ref. 1). Alamethicin, a 20- residue 
peptide produced by trichoderma viride, forms voltage gated transmembrane channels in 
phospholipid bilayer membranes (ref. 2 )  and is the best studied member of this class of 
molecules (ref. 3-6). A feature of the alamethicin sequence (Fig. 1) is the presence of 
a preponderence of hydrophobic amino acids, with the central Gln (7) residue and the 
C-terminal tripeptide containing the only polar moieties. In contrast, the shorter 
Alamethicin I (11) : Ac-Aib-Pro-Aib-Ala-Aib-Ala(Aib)-Gln-Aib-Val- 
Aib-Gly-Leu-Aib-Pro-Val-Aib-Aib-Glu-Gln-Phol. 
Antiamoebin I (11) : Ac-Phe-Aib-Aib-Aib-D-Iva-Gly-Leu-Aib-Aib-Hyp- 
Gln-D-Iva-Hyp-(Pro)-Aib-Pro-Phol. 
Zervamicin IIA (IIB) : Ac-Trp-Ile-Gln-Aib(1va)-Ile-Thr-Aib-Leu-Aib- 
Hyp-Gln-Aib-Hyp-Aib-Pro-Phol. 
Efrapeptin D : Ac-Pip-Aib-Pip-Aib-Aib-Leu- p-Ala-Gly-Aib- 
Fig. 1. Sequences of some Aib containing antibiotics 
Aib-Pip-Aib-Gly-Leu-Iva-Aib-X. 
peptide antibiotics, antiamoebins (ref. 7) and zervamicins (ref. 8), contain several resi- 
dues with polar functional groups (Thr, Hyp) and also have a cluster of Pro/Hyp residues 
at the C-terminal end of the molecule. The efrapeptins (from tolypocladium inflatum) are 
poorly characterized members of the Aib containing group of peptide antibiotics. The par- 
tial sequence of a major polypeptide component of the efrapeptins (Fig. 1) has been repor- 
ted (ref. 9 ) ,  but the nature of the C-terminal basic residue remains to be established. 
The efrapeptins also contain the unusual amino acids L-pipecolic acid (Pip) and p-alanine 
( p -Ala). Furthermore, while alamethicin, zervamicins and antiamoebins function as mito- 
chondrial uncouplers of varying efficiencies (ref. 10, ll), the efrapeptins are potent 
inhibitors of mitochondrial ATP-synthase (ref. 12). Structural investigations of Aib 
containing synthetic model peptides have provided definitive evidence for the role of Aib 
in promoting helical backbone folding (ref. 13-15). This has led to channel models for 
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alamethicin composed of clusters of largely hydrophobic helices in lipid bilayers (ref. 
1, 3)., with voltage gating suggested to arise from interaction of the macroscopic helix 
dipole with the applied electric field (ref. 16, 17). This report summarises some studies 
on antiamoebins, zervamicins and efrapeptins. 
PEPTIDE ISOLATION ANF PURIFICATION 
Zervamicins were isolated from cultures of emericellopsis salmosynnemata (strain CMI 58330) 
(ref. 18). An HPLC profile of a mixture of "zervamicins" is shown in Fig. 2. Peaks at 
23-26 min. arise from acidic zervamicin components, which have been previously identified 
as possessing a single Glu residue at position 3 (ref. 8). The component at w 2 6  min. 
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Fig. 2. HPLC profile of a mixture of zerva- 
micins. C18, 5 + ,  6 x 150 mm column. 
Gradient of methanol-water, 65-75% methanol 
in 15 min., 75-78% in 12 min., 78-81% in 60 
min. Detection 280 nm (bottom) and 226 nm 
(top). 
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Fig. 3. HPLC profile of a mixture of efra- 
peptins. C8, l o p ,  4 x 250 mm column. 
Gradient of methanol-water-0.1% TFA, 60- 
70% methanol in 15 rnin., 70-75% in 10 
min., 75-80% in 15 min. (inset) C4, 1 0 ~ ,  
4.6 x 250 mm column. Gradient of metha- 
nol-water-0.1% TFA, 65-75% methanol in 
30 rnin., 75-95% in 10 min. Detection 
226 nm. 
corresponds to the peptide zervamicin IC (ZIC). 
peptides with the major components corresponding to the previously sequenced peptides, 
zervamicins IIA (ZIIA) and IIB (ZIIB), respectively. The peak at 57.4 min. is a peptide 
which lacks the amino terminal Trp residue, characteristic of the zervamicins sequenced 
earlier (ref. 8). The absence of Trp is clearly suggested by a comparison of the HPLC 
profiles obtained by detection at 226 nm and 280 nm (Fig. 2). This peptide (2-L), has 
been shown to possess a Leu residue in place of  Trp at the amino terminus and a tentative 
sequence is Ac-Leu-Ile-Gln-Iva-Ile-Thr-Aib-Leu-Aib-Hyp-Gln-Aib-Hyp-Aib-Pro-Phol. Suppor- 
ting evidence for this assignment comes from the observation of a nuclear Overhauser effect 
(NOE) between the amino terminal blocking acetyl methyl protons and the NH proton of a Leu 
residue. The molecular mass, 1764 daltons, (FAB mass spectrum) is also consistent with 
this sequence assignment. 
inflatum niveum (strain IMI 202309) (ref. 19). The crude peptide mixture, inhibited 
oxidative phosphorylation in rat liver mitochondria. Fig. 3. shows an HPLC profile of the 
peptide mixture. 
conditions. Preliminary fractionation into components I-IV (Fig. 3 )  and analysis by mass 
spectrometry revealed that I has a major component with a molecular mass of 1619 and a 
minor component of 1605 daltons. Fractions 11, 111 and IV have components with molecular 
masses of 1633, 1647, 1661 and 1675, respectively. The strongly hydrophobic and basic 
nature of the peptide limited further HPLC purification under the conditions used. 
inset to Fig. 3 shows an HPLC profile obtained on a less hydrophobic C4 column. 
progress is directed towards elucidating the sequence relationships of the efrapeptin 
components. Antiamoebins, from emericellopsis poonensis Thirum, were obtained as described 
elsewhere (ref. 11). 
Peaks between 36-52 min. are all neutral 
Efrapeptins were isolated from cultures of tolypocladium 
The peaks were extremely broad and overlapping under a wide variety of 
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STRUCTURAL CHEMISTRY 
The Pro/Hyp rich C-terminal tail in the antiamoebins and zervamicins should lead to an 
interruption of the continuous intramolecular hydrogen bonding pattern expected in helical 
Aib peptide structures (ref. 13-15). In the case of efrapeptins the presence of pipecolic 
acid (Pip), a proline homolog, and p-alanine ( p -Ala) should lead to deviations from 
ideal helical conformations. An apolar synthetic analog of zervamicin IIA (Boc-Tfp-Ile- 
Ala-Aib-Ile-Val-Aib-Leu-Aib-Pro-Ala-Aib-Pro-Aib-Pro-Phe-OMe) has been studied by H-NMR. 
Analysis of temperature dependence and solvent perturbation of NH chemical shifts in DMSO 
and chloroform solutions suggested that a large number of amide NH groups are inacessible 
to solvent. In chloroform, with the exception of Trp (1) and Ile (2) NH groups, all the 
other NH groups are solvent shielded consistent with a completely helical conformation for 
the synthetic peptide. This is further supported by the observation of N.H <-> N.+lH NOES 
throughout the sequence, in chloroform. A partial unfolding of the structure at the amino 
terminus is observed in the strongly solvating medium DMSO, with the NH groups of Ala (3), 
Aib ( 4 )  and Ile (5) also being exposed to solvent. Interresidue NOES of the type 
fH <-> N H, observed for residues 1 to 4 ,  suggest an extended conformation for this 
pkrtion o$+hhe molecule, in DMSO. X-ray diffraction studies of crystals obtained from 
methanol-water mixtures revealed a completely helical structure in the solid-state 
[Fig. 41 with all the prolines being comfortably accomodated into a 3 helical structure, 
which has been termed as the " b-bend ribbon" (ref. 20). Natural zervamicin IIA has also 
been examined in detail by 2D NMR at 270 MHz and 500 MHz, in DMSO and methanol. Evidence 
for helical folding of residues 5 to 16 is obtained, with a partially unfolded amino 
terminus. 
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Fig. 4 .  (left) Molecular conformation of a synthetic apolar zervamicin 
analog, in crystals (ref. 20). (right) Backbone conformation of anti- 
amoebin I derived from NMR data (ref. 11). 
An NMR study of the major component of antiamoebin has indeed, also provided firm evidence 
for a largely helical conformation. 
terminus [Phe(l)-Aib(2)], a segment of left-handed helix followed by a Type I1 a-turn at 
Leu-(7)-Aib(8) and a right handed helix for residues 9 to 16 (ref. 11). A backbone confor- 
mation generated using these NMR derived parameters bears a remarkable resemblence to the 
crystal structure of the synthetic zervamicin analog (Fig. 4 ) ,  although the precise 
torsional angles used are different. However, the Pro/Hyp rich C-terminus structures are 
almost identical. Structural information on the efrapeptins has been derived indirectly, 
using a synthetic 16-residue analog peptide sequence (Boc-Pro-Aib-Pro-Aib-Aib-Leu- b-Ala- 
Gly-Aib-Aib-Pro-Aib-Gly-Leu-Aib-Aib-OMe) in which the following replacements have been 
made; Pip to Pro, Iva to Aib. The unidentified C-terminal residue is absent. NMR ana- 
lysis of this peptide in chloroform and DMSO solutions provides clear evidence for the 
solvent inaccessibility of all the amide protons except Aib (2) NH in CDC13. In DMSO, 
Gly (8), Aib (9) and Aib (15) NH groups are solvent exposed, in addition to Aib (2) NH. 
The chloroform structure is clearly a continuous helix in which both p-Ala (7) and Pro 
(11) are accomodated in the helix. The additional CH group in p-Ala is presumably 
accomodated within an eleven or fourteen membered hydrogen bonded ring as opposed to the 
ten or thirteen membered rings in ideal 310- or &-helical structures, respectively. 
NOE evidence supports a Type I1 p-turn at the N- 
2 
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The fragility of the structure in the vicinity of the central Leu- p -Ala-Gly region is 
evident in DMSO, where the Gly (8) and Gly (9 )  NH groups are solvent exposed. NMR studies 
on the hexapeptide Boc-L-Pip-Aib-Gly-Leu-Aib-Aib-OMe, (residues 12-16 of efrapeptin) 
support a helical conformation similar to that observed for the analog peptide with Pro 
in the place of Pip. Crystal structures of model pipecolyl peptides suggest that the 
conformational properties of Pip residues are fairly similar to those of proline 
(ref. 21). 
MEMBRANE MODIFYING ACTIVITY 
Both antiamoebin and zervamicin exhibit mitochondrial uncoupling activity suggesting their 
incorporation into the inner mitochondrial membrane. The synthetic, apolar zervamicin 
analog is appreciably less effective as aq+uncoupler. Similar behaviour was also 
observed in studies of peptide induced Ca fluxes across liposomal membranes. An 
interesting feature of the zervamicins, particularly the synthetic analog is the tendency 
to cause liposome aggregation as evidenced by a dramatic increase in Rayleigh scattering 
on addition of peptide to liposomes. Single channel conductance activity in planar 
bilayers has also been observed for zervamicins IIA, IC and Z-L as well as the synthetic 
analog peptide. The life times of the channels formed by the synthetic apolar analog are 
dramatically shortened compared to those for the polar peptides (M.S.P. Sansom, personal 
communication). This is consistent with the involvement of polar side-chain functiona- 
lities in stabilizing channels formed by helix association in phospholipid bilayers. 
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